Do more targets allow more cancer treatments, or not?

Article Oncology

70MO Genomic profiling to expand precision cancer medicine in the real world: The ROME trial

A. Botticelli et al.

ESMO Open (2023)

Article Multidisciplinary Sciences

Development and validation of ACTE-MTB: A tool to systematically assess the maturity of molecular tumor boards

Tara M. Love et al.

Summary: This study developed and validated a tool called ACTE-MTB to assess the maturity of molecular tumor boards (MTBs) and identify areas for improvement. The tool was tested on 20 MTBs and found that academic institutions had higher overall maturity levels than non-academic institutions, but there was a disconnect in the access domain. ACTE-MTB is the first universally-applicable tool for structured assessment of MTB maturity.

PLOS ONE (2022)

添加到收藏夹

Review Oncology

Patient attrition in Molecular Tumour Boards: a systematic review

Hannah Frost et al.

Summary: This article investigates patient attrition and barriers to treatment within Molecular Tumour Boards (MTBs). The study finds that only 20% of patients receive treatment through MTB, with reasons for not receiving treatment including no mutations identified, no actionable mutations, and clinical deterioration. However, incomplete data due to inconsistent reporting is a common issue.

BRITISH JOURNAL OF CANCER (2022)

添加到收藏夹

Review Genetics & Heredity

Clinical cancer genomic profiling

Debyani Chakravarty et al.

Summary: Profiling tumors by next-generation sequencing has the potential to improve diagnostic accuracy, assess heritable cancer risk, and guide treatment selection. Through integrative analyses of tumor and germline variants, as well as identifying mutational signatures that influence therapy response, the clinical utility of cancer genomic profiling is being enhanced. Rapid technological innovation and reduced sequencing costs have enabled the profiling of hundreds of cancer-associated genes as part of routine cancer care.

NATURE REVIEWS GENETICS (2021)

添加到收藏夹

Article Oncology

Evolution of the Randomized Clinical Trial in the Era of Precision Oncology

Joseph C. Del Paggio et al.

Summary: The study indicates that contemporary oncology RCTs mainly measure putative surrogate endpoints and are predominantly funded by the pharmaceutical industry. The increase in the involvement of medical writers is notable. The oncology community needs to evaluate whether study endpoints and target effect sizes truly benefit patients.

JAMA ONCOLOGY (2021)

添加到收藏夹

Article Oncology

Molecular Tests and Target Therapies in Oncology: recommendations from the Italian workshop

Carmine Pinto et al.

Summary: The increasingly precise and extensive characterization of tumors through gene profiling allows for better understanding of molecular mechanisms and more personalized therapeutic options. The introduction of new technologies like NGS and liquid biopsy has played a significant role in precision medicine, although challenges remain in developing guidelines for its implementation.

FUTURE ONCOLOGY (2021)

添加到收藏夹

Review Economics